Danvatirsen
Danvatirsen is a pharmaceutical drug with 6 clinical trials. Currently 4 active trials ongoing. Historical success rate of 50.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
4
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
50.0%
1 of 2 finished
50.0%
1 ended early
4
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
Clinical Trials (6)
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6